Market Cap | 4.12M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -628.58k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -8.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -29.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -65.00% |
Recommedations | - | Quick Ratio | 0.02 | Shares Outstanding | 148.32M | 52W Low Chg | 39.00% |
Insider Own | 11.59% | ROA | -895.11% | Shares Float | 140.82M | Beta | 0.77 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.03 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 53,551 | Target Price | - |
Oper. Margin | - | Earnings Date | Nov 27 | Volume | 5,085 | Change | 0.00% |
Nova Mentis Life Science Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is based in Vancouver, Canada.